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Abstract
Introduction: HIV testing is the entry point for the elimination of mother-to-child transmission of HIV. Decreasing external
funding for the HIV response in some low- and middle-income countries has triggered the question of whether a focused
approach to HIV testing targeting pregnant women in high-burden areas should be considered. This study aimed at determining
and comparing the cost-effectiveness of universal and focused HIV testing approaches for pregnant women across high to very
low HIV prevalence settings.
Methods: We conducted a modelling analysis on health and cost outcomes of HIV testing for pregnant women using four
country-based case scenarios (Namibia, Kenya, Haiti and Viet Nam) to illustrate high, intermediate, low and very low HIV
prevalence settings.We used subnational prevalence data to divide each country into high-, medium- and low-burden areas, and
modelled different antenatal and testing coverage in each.
Results: When HIV testing services were only focused in high-burden areas within a country, mother-to-child transmission rates
remained high ranging from 18 to 23%, resulting in a 25 to 69% increase in new paediatric HIV infections and increased future
treatment costs for children. Universal HIV testing was found to be dominant (i.e. more QALYs gained with less cost) compared to
focused approaches in the Namibia, Kenya and Haiti scenarios. The universal approach was also very cost-effective compared to
focused approaches, with $ 125 per quality-adjusted life years gained in the Viet Nam-based scenario of very low HIV prevalence.
Sensitivity analysis further supported the findings.
Conclusions: Universal approach to antenatal HIV testing achieves the best health outcomes and is cost-saving or cost-effective
in the long term across the range of HIV prevalence settings. It is further a prerequisite for quality maternal and child healthcare
and for the elimination of mother-to-child transmission of HIV.
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Introduction
The prevention of mother-to-child transmission (PMTCT) of
HIV by providing antiretroviral therapy (ART) to HIV-positive
pregnant women is a highly effective intervention to prevent
new HIV infections among infants. Globally, an estimated
220,000 children were newly infected with HIV in 2014, a
decline of 58% from what was estimated for 2000 [1]. Several
countries are moving towards the elimination of mother-
to-child transmission (MTCT) of HIV.
HIV testing is the entry point to PMTCT. The elimination of
MTCT requires high coverage for both HIV testing and ART;
global criteria for elimination include a]95% coverage of HIV
testing among pregnantwomen and]90% of ARTcoverage of
HIV-positive pregnant women [2].There has been a substantial
scale-up in HIV testing in antenatal care (ANC) settings; yet, in
2014 only about half of pregnant women in low- and middle-
income countries received HIV testing services [3].
Resources invested in the HIV response in low- and middle-
income countries reached $ 21.7 billion in 2015, of which 57%
came from domestic sources [1]. Calls for sustainable financing
and effective use of resources are stronger than ever [46].
Flat and decreasing external funding for HIV in low- and
middle-income countries has triggered a question of whether
a focused approach to HIV testing targeting pregnant women
in high-burden areas should be considered as a more cost-
effective alternative to universal testing. This is particularly a
pressing question for countries with limited domestic re-
sources and heavy reliance on external funding.While previous
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studies confirmed the cost-effectiveness of PMTCT services
across high- to low-income settings [713], little has been
examined on the cost-effectiveness of a focused approach.
This study aimed at examining and comparing the cost-
effectiveness of universal and focused approaches in providing
HIV testing services for pregnantwomen in ANC settings across
a spectrum of HIV prevalences. This study was conducted as
part of the development of the WHO consolidated guidelines
on HIV testing services 2015 [14].
Methods
We conducted a modelling analysis on health and cost
outcomes of HIV testing for PMTCT of HIV. We used the
Costing Tool for Elimination Initiative, which was developed to
estimate the health and cost impact of PMTCT services at
national or sub-national levels andwas used in Zambia, the Lao
People’s Democratic Republic and several countries in the
Region of the Americas [7,15]. This is an Excel-based tool,
publicly available in English, Spanish and French. The details
about the tool are also discussed elsewhere [16]. Probabilities
of MTCTwere based on the estimates provided by the UNAIDS
Reference Group on Estimates, Modelling and Projections,
which consider both peripartum and postnatal transmission
during the breastfeeding period. The analysis was conducted
from a health systems perspective, consistent with those of
Ministry of Health.
Country-based case scenarios
We developed four country-based scenarios to illustrate high,
intermediate, low and very low national HIV prevalence
settings based on published epidemiological data and reports
[1725]. Namibia (with a national HIV prevalence of 17%
among females aged 15 to 49 years), Kenya (7%), Haiti (3%) and
Viet Nam (with HIV prevalence of 0.1% among ANC attendees)
were selected according to their prevalence levels and
availability of sub-national demographic and epidemiological
data. Each country was divided into high-, medium- and low-
burden areas based on their sub-national HIV prevalence. We
used HIV prevalence among pregnant women where available;
otherwise, the prevalence among women aged 15 to 49 was
used to determine the HIV burden in sub-national areas. The
summary of demographic, epidemiological and programmatic
data used to develop these country-based cases and their
sources are presented in Table 1.
The model started with an annual cohort of pregnant
women in each country. The base case analysis used the data
of current PMTCT service coverage presented in Table 1 as the
current approach, followed by the analysis of three different
approaches of HIV testing among pregnant women, namely, a
highly focused approach, a focused approach and a universal
approach. Details of these approaches are summarized in
Figure 1. First, in the highly focused approach, we assumed
that in high-burden areas 95% of pregnant women attended
ANC at least once, 95% of ANC attendees received HIV testing
and 95% of those who tested HIV positive received ART
(i.e. the best PMTCT coverage). In medium- and low-burden
areas, we assumed that only 20% of ANC attendees received
HIV testing (i.e. low PMTCT coverage, which consisted of the
country’s current ANC coverage, 20% HIV testing coverage
among ANC attendees, and 95% ART coverage among those
who tested HIV positive). Second, in the focused approach,
both high- and medium-burden areas had the best PMTCT
coverage and the low-burden area had low PMTCT coverage.
Finally, in the universal approach, we assumed that all areas
had the best PMTCT coverage.
Virtual country scenario
A virtual country case scenario was developed to conduct
sensitivity analysis to further examine the impact of the
focused approach beyond the four country-based case
scenarios. The levels of national HIV prevalence and other
key parameters were varied. It was assumed that the number
of annual live births was 1,000,000. The country was divided
into high- and low-burden areas, and women aged 15 to 49
were assumed to live equally distributed among them. We
also assumed that 70% of all HIV-positive women lived in the
high-burden areas. Based on the World Health Statistics 2014
and the Global Update on the Health Sector Response to HIV
2014, we assumed the current coverage of PMTCT services as
follows: ANC 75%, HIV testing among pregnant women 74%
and ART among HIV-positive pregnant women 67% [17,26].
The summary of assumptions used for the virtual country
scenario and the approaches analyzed are included in
Supplementary Table 1.
We examined 1) the current approach (current PMTCT
coverage for all areas), 2) a focused approach with the best
PMTCT coverage for high-burden areas and low coverage for
low-burden areas and 3) a universal approach with the best
PMTCT coverage for all areas. HIV prevalence was varied
between 20 and 0.0005%. The sensitivity analysis also varied
the following parameters: proportion of HIV-positive women
living in high-burden area, cost of HIV testing and paediatric
treatment cost for infected children.
Assumptions and model inputs
We assumed that pregnant women were tested for HIV at
their first ANC visit. We applied two WHO-recommended
testing strategies: one for high-prevalence settings (]5%)
and the other for low-prevalence settings (B5%). Retesting
of all HIV-negative pregnant women for high-prevalence
settings, as well as all HIV-positive pregnant women before
initiating ART, was also factored in as per WHO recommenda-
tions [14]. We assumed that women identified as HIV
positive received ART regardless of WHO clinical stage and
at any CD4 cell count, all women breastfed for 12 months and
exposed children were followed up through the age of 18
months based on WHO recommendations [27,28]. The
cost of future paediatric HIV treatment for 20 years was
estimated assuming infected children receive ART based on
the regimens recommended by WHO at the time of this
analyses [27].
Unit costs for HIV rapid testing, early infant diagnosis, CD4
and viral load monitoring were estimated based on the unit
costs from WHO and other sources [2932]. The cost of
antiretroviral (ARV) drugs was based on the WHO report [33]
and the Clinton Health Access Initiative ARV Ceiling Price
List [34]. Health service costs for each PMTCT follow-up visit
were based on WHO Choosing Interventions that are Cost
Effective [35]. We assumed that 20 quality-adjusted life years
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Table 1. Model input
Namibia (high) Kenya (intermediate) Haiti (low) Viet Nam (very low) Reference
Epidemiological data
National HIV prevalence among women aged
1549 years
17% 7% 3% 0.1%*
Sub-national HIV burden (prevalence) High
(20%)
Medium
(1020%)
Low
(B10%)
High
(10%)
Medium
(510%)
Low
(B5%)
High
(3%)
Medium
(23%)
Low
(B2%)
High
(0.2%)
Medium
(0.10.2%)
Low
(B0.1%)
Estimated proportion of women aged 1549 years
reside in the area
37% 52% 11% 14% 60% 26% 26% 51% 22% 17% 41% 41%
Estimated proportion of HIV-positive women reside in
the area
49% 46% 5% 37% 48% 16% 34% 40% 15% 36% 48% 16% [1725]
PMTCT services
ANC coverage (at least once) 97% 92% 90% 94%
HIV testing at ANC 81% 92% 61% 72%
ART for HIV-positive pregnant women 69% (85% among those
tested positive)
71% 57% (93% among those
tested positive)
65%
Cost (in USD)
Antiretroviral drugs
Maternal ART (14 weeks of pregnancy to
12 months postnatal)
208
Paediatric ART (annual cost) [34]
ABC3TCLPV/r (03 years old) 258 [33]
ABC3TCEFV (310 years old) 182
TDF/3TC/EFV (10 years old) 136
Laboratory test
HIV rapid test (per test) 0.73 [2932]
CD4 (per test) 5.56
Viral load (per test) 21.56
Early infant diagnosis (per test) 8.76
Laboratory monitoring (paediatric HIV) per year 32.86
Health services
Clinic with beds (per visit) 7.59 1.39 1.55 1.90 [35]
Primary level hospital (per visit) 8.65 1.59 1.77 2.17
GDP per capita 5589 1358 824 2052 [39]
Quality-adjusted life years (QALYs)
QALYs gained per infant infection averted 20 [36,37]
ABC, abacavir; ANC, antenatal care; ART, antiretroviral therapy; CD4, Tlymphocyte cell bearing CD4 receptor; EFV, efavirenz; GDP, gross domestic product; LPV/r, lopinavir/ritonavir; TDF, tenofovir
disoproxil fumarate; 3TC, lamivudine; *, among ANC attendees.
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(QALYs) would be gained by averting a new paediatric HIV
infection [36,37]. The main model inputs are summarized in
Table 1.
Main outcomes
We estimated the number of HIV-positive pregnant women
identified, the number of new paediatric HIV infections, the
number of paediatric infections averted and the MTCT rate
per annual cohort of pregnant women.We also estimated the
total cost of HIV testing, PMTCT services and the future cost
of paediatric HIV treatment. Costs were discounted at 3%
annually. We then compared these outcomes by different
testing approaches and performed cost-effectiveness analysis.
The incremental cost-effectiveness ratios (ICERs) as the
incremental cost per paediatric infection averted or per QALY
gained in comparisons with the next least-expensive alter-
native approachwere estimated. FollowingWHOguidance, we
considered approaches with ICERs below the gross domestic
product (GDP) per capita to be ‘‘very cost-effective’’ and that
below three times of GDP to be ‘‘cost-effective’’ [38].
Results
Country-based case analysis
Under the highly focused approach, the estimated propor-
tions of pregnant women living in the focused areas ranged
from 14 to 37%, which was expected to capture 34 to 49%
of HIV-positive women in these country scenarios. For the
focused approach, the estimated proportions of pregnant
women and women living with HIV in the focused areas were
between 58 and 89% and 74 and 95%, respectively.
The summary results are presented in Table 2 and Figure 2.
Under the current approach, MTCT rates were estimated
between 12 and 17% in the four country cases. Health
outcomes including the number of infections averted, MTCT
rate and QALYs gained were superior for the focused and the
universal approaches compared with the current approach. In
contrast, the highly focused approach resulted in the poorest
health outcomes, including higher MTCT rates between 18
and 23%. Higher paediatric treatment costs were also obser-
ved under the highly focused approach in all scenarios, for
example, over a 60% increase in the Kenya- and Viet Nam-
based cases compared with the current approach.
The provision of PMTCTservices was found to be cost-saving
in all country cases and approaches when compared with no
PMTCT intervention. When both PMTCT costs and the future
paediatric treatment costs were considered, the universal
approachwas dominant (i.e. more QALYs gained with less cost)
compared with the focused and highly focused approaches in
the Namibia-, Kenya- andHaiti-based country cases by averting
more infections with lower total costs. In Viet Nam-based
scenario, the universal approach averted more HIV infections
with relatively similar total costs compared with the focused
and highly focused approaches; and the universal approach
was found to be very cost-effective comparedwith the focused
approach, with an additional $ 125 per QALYgained.When only
PMTCT costs were considered, the cost per QALY gained by
averting new HIV infections among infants still remained
below the GDP per capita in all country scenarios including Viet
Nam (Supplementary Table 2).
Virtual country scenario
We conducted sensitivity analysis using virtual country case
scenarios, by varying levels of HIV prevalence between 20
and 0.0005% as well as other key parameters as shown in
Supplementary Table 1. Under the assumption that 70% of
women livingwith HIV reside in high-burden areas, the focused
approach was found to result in poor outcomes including
higher MTCT rates and increased number of new paediatric
HIV infections compared with the universal approach. These
findings remained constant across the different levels of HIV
prevalence.
Both the universal and focused approaches were found to
be cost-saving compared with no intervention, even when HIV
prevalence was as low as 0.08%. This finding was robust even
with higher health service costs and different proportions of
HIV-positive women living in high-burden areas. When the
cost of paediatric treatment was varied and increased to
$ 300 per person per year, all approaches were found to be
consistently cost-saving, including with HIV prevalences as low
as 0.05%. When the cost of paediatric treatment was
increased to $ 1000 per person per year, the approaches
were still cost-saving at HIV prevalence of 0.02%.
We calculated the cost per QALY gained based on PMTCT
programme costs and future paediatric treatment costs. Our
analysis found that the universal approach with the best
PMTCT coverage was dominant compared with the focused
approachwith an HIVprevalence of down to 0.25%.The ICERof
the universal approach compared with the focused approach
Approach High HIV burden Medium burden Low burden
Current Current PMTCT service coverage in each country
Highly focused Best PMTCT coverage* 
Focused Low PMTCT coverage**
Universal
* ANC coverage 95%, HIV testing among ANC attendees 95%, ART coverage among those tested positive 95%
**  Current ANC coverage, HIV testing among ANC attendees 20%, ART coverage among those tested positive 95%
Subnational area
Figure 1. Approaches examined in each country scenario.
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Table 2. Health outcomes, costs and cost-effectiveness of different HIV testing approaches in four country-based scenarios (per 1,000,000 pregnant women)
Health outcomes Costs (USD thousands) ICERa
Country-based case
(HIV prevalence among
pregnant women) Approach
MTCT
Rate
(%)
Number of
HIV women
identified
Number of
new paediatric
infections
Number
paediatric
infections averted
Quality-adjusted
life years (QALYs)
gained
PMTCT (HIV
test, ARVs, and
health services)
Paediatric
treatment
(20 years)
Total cost (PMTCT
including HIV testing &
paediatric treatment)
Cost
savedb
USD per
QALY
saved
Namibia (17%) Universal 7 155,765 11,740 43,102 862,040 49,604 27,654 77,258 128,616
Focused 8 148,803 13,667 41,175 823,508 47,324 32,152 79,476 126,398 Dominatedc
Current 12 138,221 20,621 34,221 684,426 39,651 48,385 88,035 117,838 Dominated
Highly
focused
18 89,710 30,019 24,824 496,475 28,446 70,322 98,768 107,106 Dominated
Kenya (7%) Universal 6 65,658 4350 21,551 431,016 17,055 9121 26,175 60,448
Focused 10 57,366 7053 18,848 376,953 14,785 14,751 29,536 57,087 Dominated
Current 13 63,584 9041 16,860 337,200 13,610 18,891 32,501 54,122 Dominated
Highly
focused
22 32,175 15,266 10,635 212,703 8096 31,856 39,952 46,671 Dominated
Haiti (3%) Universal 8 21,646 1838 6434 128,689 5915 3864 9778 17,976
Focused 11 18,731 2705 5568 111,357 5089 5674 10,763 16,992 Dominated
Current 17 14,635 4014 4259 85,178 3926 8408 12,334 15,420 Dominated
Highly
focused
21 10,923 5026 3247 64,937 2921 10,522 13,444 14,310 Dominated
Viet Nam (0.1%) Focused 11 1020 139 378 7565 694 292 987 759
Highly
focused
23 577 303 214 4284 370 638 1008 738 Dominated
Universal 6 1168 84 433 8663 947 177 1123 622 125
Current 15 932 188 328 6569 744 397 1141 605 Dominated
aBased on total cost (i.e. PMTCT cost including HIV testingpaediatric treatment cost); bcost saved(total costs of no PMTCT intervention)  (total costs of selected approach), where total cost includes
HIV testing costsPMTCT costpaediatric treatment costs for 20 years; can approach that is more expensive and less effective than an alternative approach. MTCT, mother-to-child transmission; PMTCT,
prevention of mother-to-child transmission.
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was $ 101 per QALYgained at an HIV prevalence of 0.1%, which
is well below the GDP per capita in low- and middle-income
countries. When prevalence was reduced to 0.01%, the ICER
was $ 1673, which was still highly cost-effective for a low HIV
prevalence country like Viet Nam with a GDP per capita of $
2052 [39]. When compared with the current approach, the
universal approach was still cost-effective at an HIV prevalence
of 0.005% with GDP per capita of $ 1000.
To examine the impact of sub-national prevalence, the
proportion of HIV-positive women in the high-burden areas
was varied between 50 and 90% (Figure 3). The universal
approach was dominant with an HIV prevalence of 0.3%, with
75% of HIV-positive women living in high-burden areas. Under
an HIV prevalence of 0.1%, the ICER increased to $ 451 per
QALY gained when 90% of HIV-positive women lived in high-
burden areas, which was still well below GDP per capita of
most low-income countries [39], and thus regarded as
very cost-effective. With a prevalence of 0.01% and 90% of
HIV-positive women residing in high-burden areas, the ICER
was estimated at $ 5165 per QALY gained, which could still be
cost-effective.
Discussion
We analyzed the cost-effectiveness of universal and focused
approaches to antenatal HIV testing across different HIV
prevalence settings. We found that the universal approach
identifies most HIV-positive mothers, minimizes the number
of infections among infants and saves resources by averting
future paediatric treatment costs. Although it requires more
upfront costs, the universal approach leads to better health
outcomes and is cost-saving or cost-effective in the long term.
To our knowledge, this is the first study to compare the
health and cost impacts of different HIV testing approaches
for pregnant women using country-based scenarios across
different HIV epidemiological profiles. This is particularly
relevant when considering elimination of mother-to-child
HIV transmission in a context of limited resources and
optimized investment.
The cost-effectiveness of PMTCT services has been exam-
ined in several countries in the past. Early research, mostly
conducted in high-income countries in the late 1990s and the
early 2000s, analyzed the cost-effectiveness of universal
testing in ANC settings. Studies from the United Kingdom
and Australia addressed the provision of universal antenatal
HIV screening and its cost-effectiveness in settings of very
low HIV prevalence [8,9]. Both studies concluded that
universal HIV testing would be cost-effective even with very
low HIV prevalence and recommended its inclusion in routine
ANC. Currently, HIV screening is considered as a component of
standard antenatal care in many countries [4044].
Recent studies on PMTCT in sub-Saharan Africa, where HIV
prevalence is high and universal HIV testing for pregnant
Figure 2. Summary health and cost outcomes of different approaches in four country-based scenarios (per 1,000,000 pregnant women).
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women is strongly recommended, analyzed the cost-
effectiveness of different options for PMTCT services and
concluded that they were cost-effective [7,1012]. An
analysis of PMTCT programmes in New York State between
1998 and 2013 found that every $ 1 invested in PMTCT,
$ 4 has been saved in HIV treatment costs; and concluded that
it justified the allocation of resources for PMTCT [13]. Our
analysis supports the evidence from the past studies that
PMTCT with universal antenatal HIV testing is a cost-saving
and cost-effective intervention even in low HIV prevalence
settings.We also found that the universal approach proved to
be very comparable with other priority interventions such as
early initiation of ART in serodiscordant couples ($ 590 per
life-year saved in South Africa; $ 442 per QALY gained in India)
in terms of its cost-effectiveness [45,46].
In the current environment of flat-lined and decreasing HIV
funding [1], there has been a call by external donors and
partners for more efficient allocation of resources, including
the focused and prioritized HIV testing approaches targeting
high HIV burden areas [5]. Our comparison of the universal
and focused approaches found that while the focused
approach would imply decreased expenditure for HIV testing
and PMTCT services in the short term, it would result in
higher expenditure in the long term due to a larger number
of new paediatric infections. The universal approach was
dominant in preventing more paediatric HIV infections with
lower total costs even in ANC settings with HIV prevalence
as low as 0.25%. The universal approach maintained cost-
effectiveness in settings with an HIV prevalence of 0.003%
and GDP per capita of $ 2000. Even in a scenario where 90%
of HIV-positive women live in high-burden areas, the
universal approach was still cost-effective.
The findings of this study should be interpreted taking into
consideration the following limitations. We may have under-
estimated the health impact of interventions since the health
benefit for women starting early ART and its impact on
HIV transmission among serodiscordant couples were not
included in our analysis. The future cost-savings may be
underestimated as our model used the low-end cost for
paediatric treatment and limited the treatment time horizon
to 20 years. In addition, we did not discuss or model the
potential additional benefits of bundling HIV testing, with
syphilis or hepatitis B testing. We adopted a conservative
approach and believe that these limitations would, in fact,
further strengthen the argument in favour of the universal
approach, as the benefits and the cost-effectiveness of PMTCT
interventions on maternal health outcomes and prevention of
partner infection are well documented [7,11,47]. We are also
aware that our scenario did not take into account the non-
breastfeeding population, which may have resulted in over-
estimation of MTCT rates. It should also be noted that our
scenarios are not exhaustive; we are aware of country-specific
epidemic situations that may not fit into any of the four cases,
including the coexistence of different HIV epidemic situations
among certain populations within the same country. It should
also be noted that our parameters of ‘‘best PMTCT coverage’’
do not support achievement of the elimination target of B5%
MTCT rates, as they only assume an 86% ART coverage among
HIV-positive women (as a result of 95%ANC coverage, 95%HIV
testing among ANC attendees and 95% ART coverage among
those who tested HIV positive). Our scenarios did not take into
account potentially lower rates of ANC attendance among
women at higher risk of HIV infection, particularly women who
inject drugs and young women involved in transactional sex
who are often marginalized. Countries with low or variable
ANC coverage need to consider additional investments for
reaching women and linking them to ANC services, particularly
those at higher risk of HIV infection who may not access ANC.
The universal approach is optimal when striving towards
the elimination of new paediatric HIV infections. The question
to be answered is: should we invest now to prevent new HIV
infections or pay later for HIV treatment? Countries with
limited resources may face a difficult decision in allocating
currently available funds among many competing priorities.
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Figure 3. Sensitivity analysis on the impact of HIV prevalence and proportion of HIV-positive pregnant women residing in high-burden areas
(universal vs. focused approach).
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For countries facing resource challenges, a focused approach
could be applied in the short term as an interim measure
and then scale up to a universal approach as resources are
identified to provide universal HIV testing for pregnant
women. Last but not least, access to HIV testing for all
people, including women and children living in non-focused
areas who wish to be tested, needs to be ensured.
Conclusions
Universal approach to antenatal HIV testing achieves the best
health outcomes and is cost-saving or cost-effective in the
long term across the range of HIV prevalence settings. It is
further a prerequisite for quality maternal and child health-
care and for the elimination of MTCT of HIV.
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